A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I

Thrombosis and Haemostasis

Volumn 87, Issue 2, 2002, Pages 231-237

  Eriksson, Bengt I ^a   Arfwidsson, Ann Christin ^a   Frison, Lars ^a   Eriksson, Ulf G ^a   Bylock, Anders ^a   Kälebo, Peter ^a   Fager, Gunnar ^a   Gustafsson, David ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Deep vein thrombosis; H 376 95; Melagatran; Oral direct thrombin inhibition; Thrombin inhibitors; Ximelagatran

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTHROPLASTY; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; ELECTIVE SURGERY; EVALUATION; FEMALE; HERNIA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTICENTER STUDY; ORTHOPEDIC SURGERY; PARALLEL DESIGN; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 0036171348     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612978     Document Type: Article

References (21)

1. Prevention of venous thromboembolism
2. Deep-vein thrombosis
3. European Consensus Statement. Prevention of venous thromboembolism
4. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
5. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - Comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban
6. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development
7. Prevention of deep vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
8. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
9. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects
10. Single and repeated oral dosing of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects
11. Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration
12. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat
13. Antithrombotic effects of thrombin inhibitors and warfarin in the rat
14. Prophylaxis of venous thromboembolism with melagatran, given subcutaneously after total hip or total knee replacement: Results from Phase II studies
15. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
16. Roentgen diagnosis of venous thrombosis in the leg
17. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment
18. Ventilation-perfusion studies in suspected pulmonary embolism
19. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
20. Less influence on liver enzymes with recombinant hirudin, CGP 39393 (™Revasc - Ciba), compared to unfractionated heparin, in patients undergoing total hip replacement
21. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes